Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.
These two policy briefs explore two as yet untapped sources for drug-resistant tuberculosis (DR-TB) research funding within the U.S. Department of Health and Human Services (HHS).
These free educational materials are designed for community-based and civil society organizations to use to advocate for and teach people about TB preventive treatment (TPT).
In October 2023, sixteen members of the global TB community developed a consensus statement on the inclusion of pregnant and breastfeeding women and persons in TB treatment and vaccines research.
Treatment Action Group (TAG), the New-York-City-based activist research and policy think tank working to end the epidemics of HIV, TB, and hepatitis C, made leadership changes at its annual Board of Directors meeting on February 10, 2024.
We are appalled. As organisations that have historically worked on issues of health justice and access to medicines for millions of people around the world, for decades, focusing on HIV/AIDS, TB, cancer, and COVID, we share the urgent concern and outrage of aid organizations (NGOs) that the sudden decision by global north donor countries to suspend funding for the United Nations Relief and Works Agency (UNRWA) ‘’comes amid a rapidly worsening humanitarian catastrophe in Gaza."
This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.
A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.
Tuberculosis Research Funding Trends 2005 – 2022, the 18th annual installment of our series assessing the state of TB R&D, is based on surveys of biomedical research funders conducted by TAG with support from Stop TB Partnership.
TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.